Clinical ResearchAcute InfarctionPrognostic Value of Mid-Regional Pro-Adrenomedullin Levels Taken on Admission and Discharge in Non–ST-Elevation Myocardial Infarction: The LAMP (Leicester Acute Myocardial Infarction Peptide) II Study
Acute Infarction
Under an Elsevier user license
open archive
Key Words
adrenomedullin
Global Registry of Acute Coronary Events score
myocardial infarction
N-terminal pro–B-type natriuretic peptide
prognosis
Abbreviations and Acronyms
ACS
acute coronary syndrome
AM
adrenomedullin
AMI
acute myocardial infarction
BNP
B-type natriuretic peptide
eGFR
estimated glomerular filtration rate
HF
heart failure
HR
hazard ratio
MACE
major adverse cardiac event(s)
MI
myocardial infarction
NRI
net reclassification improvement
NSTEMI
non–ST-segment elevation myocardial infarction
NT-proBNP
N-terminal pro–B-type natriuretic peptide
ROC
receiver-operator characteristic
sAM
mid-regional pro-adrenomedullin abbreviated to surrogate for adrenomedullin
STEMI
ST-segment elevation myocardial infarction
Cited by (0)
Drs. Dhillon, Khan, and Narayan were supported by British Heart Foundation Junior Research Fellowships(grant numbers FS/03/028/15486, FS/03/028/15486, and FS/09/040, respectively). Dr. Ng was supported by the Leicester National Institute for Health Research Cardiovascular Biomedical Research Unitand has submitted patent applications on behalf of the University of Leicester on biomarkers of cardiovascular disease. Drs. Struck and Morgenthaler are employees of BRAHMS AG, a mid-sized company based in Hennigsdorf, Germany that commercializes immunoassays and has developed the Midregional Pro-Adrenomedullin assay, for which it owns the patent rights. Dr. Bergmann holds ownership in and is a member of the board of directors of BRAHMS AG.
Copyright © 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.